Latest News
Nicox completes key data package for NCX 470 NDA submissions
16 December 2025 - Ophthalmology company Nicox SA (Euronext Growth Paris:ALCOX) announced on Tuesday that it has completed the generation and analysis of all clinical trial and long-term stability data required to support New Drug Application (NDA) s...
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
16 December 2025 - Clinical-stage biotechnology company Immusoft of CA, a subsidiary of Immusoft Corporation, announced on Monday that it has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for ISP-002, its investigati...
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
16 December 2025 - Non-profit biotech company Orphan Therapeutics Accelerator (OTXL) announced on Monday that it has signed a Memorandum of Understanding (MoU) with Fondazione Telethon, an Italian non-profit biomedical organisation, to facilitate US ...
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
16 December 2025 - US biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Monday that it has completed the transfer of the Investigational New Drug application (IND) for its breast cancer vaccine from Cleveland Clinic.Anixa is now ...
Physiomics secures follow-on UK contract for Phase 2 study support
15 December 2025 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, announced on Monday that it has been awarded a follow-on contract with an existing UK client to support a Phase 2 clinical trial for a sma...